Penumbra Swings to Profit on Strong Revenue Growth, Absence of Impairment

TL;DR

**PEN is back in the black with strong revenue growth and no impairment hit, signaling a clear buy for traders.**

AI Summary

Penumbra Inc. reported robust financial performance for the nine months ended September 30, 2025, with revenue increasing to $1,018.28 million, up from $879.097 million in the prior year, representing a 15.8% growth. The company swung from a net loss of $19.671 million in the nine months ended September 30, 2024, to a net income of $130.344 million for the same period in 2025. This significant improvement was driven by a substantial increase in gross profit, which rose from $544.274 million to $680.309 million, and the absence of the $76.945 million impairment charge recorded in 2024. Operating expenses decreased slightly from $577.770 million to $550.293 million, despite an increase in sales, general and administrative expenses from $426.052 million to $482.321 million. Cash and cash equivalents decreased slightly from $324.404 million at December 31, 2024, to $321.029 million at September 30, 2025, primarily due to significant purchases of marketable investments totaling $146.648 million. The company's strategic outlook remains focused on developing innovative technologies for challenging medical conditions like ischemic stroke and venous thromboembolism, leveraging its computer-assisted vacuum thrombectomy (CAVT) portfolio.

Why It Matters

Penumbra's return to profitability and strong revenue growth signal a positive trajectory for investors, demonstrating effective cost management and market penetration in the medical device sector. This performance could attract more institutional investment, potentially driving up stock value. For employees, the improved financial health suggests job security and potential for growth within a company that is a 'world's leading thrombectomy company.' Customers benefit from continued innovation in critical medical technologies, particularly in stroke and venous thromboembolism treatments, enhancing patient outcomes. In the broader market, Penumbra's success reinforces the competitive landscape in medical devices, pushing rivals to innovate further in thrombectomy solutions.

Risk Assessment

Risk Level: low — The company's risk level is low due to its significant swing from a net loss of $19.671 million in 2024 to a net income of $130.344 million in 2025, demonstrating strong financial recovery and operational efficiency. Additionally, cash provided by operating activities increased from $117.373 million in 2024 to $152.179 million in 2025, indicating robust internal cash generation.

Analyst Insight

Investors should consider increasing their position in Penumbra (PEN) given the strong return to profitability and significant revenue growth. The absence of the prior year's impairment charge and increased operating cash flow suggest improved operational health and future stability.

Financial Highlights

revenue

$1,018.28M

operating Margin

12.77%

total Assets

$1,744.369M

net Income

$130.344M

eps

$3.32

gross Margin

66.81%

cash Position

$321.029M

revenue Growth

+15.8%

Revenue Breakdown

Key Numbers

• $1.018B — Revenue (Increased by 15.8% from $879.097M in 2024 to $1.018B in 2025 for the nine-month period.)
• $130.344M — Net Income (Swung from a net loss of $19.671M in 2024 to a net income of $130.344M in 2025 for the nine-month period.)
• $76.945M — Impairment Charge (Absence of this charge in 2025 significantly contributed to net income improvement compared to 2024.)
• $152.179M — Net Cash Provided by Operating Activities (Increased from $117.373M in 2024 to $152.179M in 2025 for the nine-month period.)
• $146.648M — Purchases of Marketable Investments (Significant investing activity contributing to the decrease in cash and cash equivalents.)

Key Players & Entities

• Penumbra Inc. (company) — registrant
• $1,018,280,000 (dollar_amount) — revenue for nine months ended September 30, 2025
• $879,097,000 (dollar_amount) — revenue for nine months ended September 30, 2024
• $130,344,000 (dollar_amount) — net income for nine months ended September 30, 2025
• $19,671,000 (dollar_amount) — net loss for nine months ended September 30, 2024
• $76,945,000 (dollar_amount) — impairment charge in 2024
• $321,029,000 (dollar_amount) — cash and cash equivalents at September 30, 2025
• $324,404,000 (dollar_amount) — cash and cash equivalents at December 31, 2024
• $146,648,000 (dollar_amount) — purchases of marketable investments
• Chief Executive Officer (person) — chief operating decision-maker

FAQ

Risk Factors

• Supply Chain Disruptions [medium — operational]: The company relies on a limited number of suppliers for certain components. Any disruption in the supply chain, such as those related to geopolitical events or natural disasters, could materially impact production and ability to meet demand.
• Regulatory Approval Delays [high — regulatory]: Penumbra's products are subject to stringent regulatory review by bodies like the FDA. Delays in obtaining or maintaining regulatory approvals for new products or existing product modifications can hinder market entry and revenue generation.
• Competition and Technological Advancements [medium — market]: The medical device market is highly competitive. Competitors may develop superior or more cost-effective technologies, potentially eroding Penumbra's market share and profitability.
• Marketable Investment Fluctuations [low — financial]: The company holds significant marketable investments. Fluctuations in market value could impact financial results and cash availability.
• Product Liability Claims [medium — legal]: As a manufacturer of medical devices, Penumbra faces potential product liability claims. Adverse judgments or settlements could result in significant financial costs and reputational damage.

Industry Context

Penumbra operates in the highly innovative and competitive medical device sector, specifically focusing on neuro and vascular interventions. Key trends include the increasing demand for minimally invasive procedures, advancements in AI-driven surgical tools, and a growing focus on treating complex conditions like ischemic stroke and venous thromboembolism. The market is characterized by significant R&D investment and a rigorous regulatory environment.

Regulatory Implications

Penumbra's products are subject to strict regulatory oversight from agencies like the FDA. Compliance with evolving regulations, obtaining timely approvals for new devices, and managing post-market surveillance are critical. Any failure to comply can lead to product recalls, fines, and significant reputational damage.

What Investors Should Do

1. Monitor R&D pipeline and new product approvals.
2. Analyze SG&A expense trends.
3. Evaluate the impact of marketable investment strategy.
4. Assess competitive landscape and market share.

Glossary

Impairment Charge

A reduction in the carrying value of an asset when its recoverable amount falls below its book value. (The absence of a $76.945 million impairment charge in 2025 significantly boosted net income compared to 2024.)

Marketable Investments

Securities that are readily salable in the open market. (Significant purchases of marketable investments totaling $146.648 million contributed to a decrease in cash and cash equivalents.)

Computer-Assisted Vacuum Thrombectomy (CAVT)

A medical technology used to remove blood clots, particularly in cases of stroke. (Penumbra's strategic focus includes leveraging its CAVT portfolio for treating conditions like ischemic stroke.)

Operating Lease Right-of-Use Assets

An asset representing the right to use an underlying leased asset for the lease term. (These assets, along with associated liabilities, reflect the company's leasing arrangements for property and equipment.)

Year-Over-Year Comparison

Penumbra Inc. has demonstrated significant year-over-year improvement. Revenue for the nine months ended September 30, 2025, increased by 15.8% to $1.018 billion, compared to $879.097 million in the prior year. The company achieved a substantial swing from a net loss of $19.671 million in 2024 to a net income of $130.344 million in 2025, largely due to a higher gross profit and the absence of a $76.945 million impairment charge recorded in the prior year. Operating expenses saw a net decrease despite an increase in SG&A, contributing to improved profitability.

Key Financial Figures

• $0.001 — ich registered Common Stock, Par value $0.001 per share PEN The New York Stock Exchan

Filing Documents

• pen-20250930.htm (10-Q) — 1396KB
• pen-93025xexhibit311.htm (EX-31.1) — 10KB
• pen-93025xexhibit312.htm (EX-31.2) — 10KB
• pen-93025xexhibit321.htm (EX-32.1) — 5KB
• 0001321732-25-000109.txt ( ) — 6830KB
• pen-20250930.xsd (EX-101.SCH) — 32KB
• pen-20250930_cal.xml (EX-101.CAL) — 63KB
• pen-20250930_def.xml (EX-101.DEF) — 109KB
• pen-20250930_lab.xml (EX-101.LAB) — 483KB
• pen-20250930_pre.xml (EX-101.PRE) — 335KB
• pen-20250930_htm.xml (XML) — 1229KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statements of Comprehensive Income (Loss) 4 Condensed Consolidated Statements of Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3. Quantitative and Qualitative Disclosure about Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 36

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosure 37 Item 5. Other Information 37 Item 6. Exhibits 38

Signatures

Signatures Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS. Penumbra, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 321,029 $ 324,404 Marketable investments 149,267 15,727 Accounts receivable, net of allowance for credit losses of $ 2,350 and $ 5,638 at September 30, 2025 and December 31, 2024, respectively 183,430 167,668 Inventories 432,365 406,737 Prepaid expenses and other current assets 55,429 36,589 Total current assets 1,141,520 951,125 Property and equipment, net 97,730 62,641 Operating lease right-of-use assets 170,715 177,787 Finance lease right-of-use assets 26,790 28,018 Intangible assets, net 6,368 6,513 Goodwill 166,748 165,826 Deferred taxes 94,478 100,332 Other non-current assets 40,020 40,939 Total assets $ 1,744,369 $ 1,533,181 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 29,821 $ 31,326 Accrued liabilities 124,273 112,429 Current operating lease liabilities 13,086 12,221 Current finance lease liabilities 2,423 2,369 Total current liabilities 169,603 158,345 Non-current operating lease liabilities 180,313 187,068 Non-current finance lease liabilities 21,223 21,731 Other non-current liabilities 14,534 15,106 Total liabilities 385,673 382,250 Commitments and contingencies (Note 8) Stockholders' equity: Common stock 39 38 Additional paid-in capital 1,165,195 1,096,732 Accumulated other comprehensive income (loss) 3,114 ( 5,843 ) Retained earnings 190,348 60,004 Total stockholders' equity 1,358,696 1,150,931 Total liabilities and stockholders' equity $ 1,744,369 $ 1,533,181 See accompanying notes to the unaudited condensed consolidated financial statements 2 Table of Contents Penumbra, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September

View Full Filing

View this 10-Q filing on SEC EDGAR